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Abstract
Background The impact of herpes zoster (HZ) and post-
herpetic neuralgia (PHN) on patients’ quality of life (QoL)
is currently poorly documented.
Subjects and methods Telephone interviews in Germany
identified patients ≥50 years old with painful HZ diagnosed
during the previous 5 years. Bespoke questions evaluated
previous HZ episodes.
Results Of 11,009 respondents, 280 met the screening
criteria, and 32 (11%) developed PHN. PHN was associated
with significantly worse outcomes than HZ (all P<0.05).
Mean pain scores associated with PHN and HZ, respectively,
were 7.1 and 6.2 (average) and 8.2 and 7.0 (worst). Many
patients with PHN (91%) and HZ (73%) experienced
problems with daily activities, including work, studies,
housework, family and leisure activities. Mean pain interfer-
ence scores in patients with PHN versus HZ were highest for
sleep (6.5 versus 4.9), normal work (6.1 versus 4.4) and mood
(5.9 versus 4.4). Most employed interviewees with PHN
(70%) and HZ (64%) stopped work during the disease. Pain
andQoL outcomeswere not significantly different between all
patients versus those diagnosed during the previous 12months
or between patients aged 50–59 years versus ≥60 years.
Conclusions HZ causes substantial pain, which seriously
interferes with many aspects of daily life, particularly in
patients with PHN.
Keywords Herpes zoster . Pain . Post-herpetic neuralgia .
Quality of life . Survey
Background
Herpes zoster (HZ; ‘shingles’) is a reactivation of the latent
varicella zoster virus (VZV; ‘chicken pox’)(Simpson 1954;
Weller et al. 1958; Straus et al. 1984; Lungu et al. 1995). HZ
is characterized by a vesicular skin rash, which is often
preceded or accompanied by acute pain or itching. The most
common and debilitating complication of HZ is post-herpetic
neuralgia (PHN). There is no standard definition of PHN, but
it is commonly defined as pain that persists for at least
3 months after the onset of HZ rash (Oxman et al. 2005;
Gauthier et al. 2009). Patients with PHN report various pain
types, including constant (burning, aching, throbbing),
intermittent (e.g., stabbing, shooting) and pain induced by
normally non-painful stimuli, such as cold wind or light
touch from clothing (Schmader 2001; Dworkin et al. 2008).
In Western countries, the estimated incidence of acute
HZ in the general population is 3–5 per 1,000 person-years
(annual events per 1,000 population)(Gauthier et al. 2009;
Hope-Simpson 1965; Paul and Thiel 1996; di Luzio
Paparatti et al. 1999; Chidiac et al. 2001; Brisson and
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Edmunds 2003; de Melker et al. 2006; Yawn et al. 2007).
HZ incidence increases with age because of a decline in
specific immunity against latent VZV (Arvin 2005). There
is a marked increase in annual risk starting at approximately
50 years of age that may reach >10 per 1,000 person-years
in those aged ≥80 years (Gauthier et al. 2009; Hope-
Simpson 1965; Paul and Thiel 1996; de Melker et al 2006;
Yawn et al. 2007). One in four people will contract HZ in
their lifetime, with this risk rising to one in two individuals
≥85 years old (Schmader 2001; Miller et al. 1993). The risk
of patients developing complications such as PHN
increases with age (Gauthier et al. 2009; Choo et al.
1997). PHN incidence rises rapidly after the age of 60 years
(Gauthier et al. 2009; Opstelten et al 2002; Stein et al.
2009). Data show that 10–20% of patients with HZ aged
≥50 years will develop PHN that persists at 3 months
(Oxman et al. 2005; Gauthier et al. 2009; Scott et al. 2006;
Johnson and Rice 2007).
HZ and PHN can have a devastating effect on quality of
life (QoL), affecting physical, functional, psychological and
social domains (Schmader 2001; Oster et al. 2005; Coplan
et al. 2004; Schmader 2002; van Seventer et al. 2006;
Schmader et al. 2007; Lydick et al. 1995; Katz et al 2004;
Brisson et al 2008). Patients have reduced functional
ability, with many becoming inactive or housebound. QoL
seems to be a particular problem in patients whose pain
persists as PHN (Chidiac et al. 2001; Oster et al. 2005;
Coplan et al. 2004; Schmader 2002; van Seventer et al.
2006; Mauskopf et al. 1994). Increased awareness of the
burden of HZ and PHN on QoL may lead to improved
strategies for prevention and management. The aim of this
survey was to assess the impact of HZ and PHN on the
QoL of a German population aged ≥50 years who had
experienced painful HZ during the previous 5 years.
Methods
Interviews
Interviewers from TNS Healthcare Germany contacted
randomly selected individuals in private German house-
holds between 25 March and 8 May 2008. In subjects who
could answer questions by telephone, interviews lasted
≤15 min and comprised closed questions.
The applied standard system of TNS Healthcare Germany,
‘InfraScope’ (TNS Infratest 2004), combines computer-
assisted telephone interviews with computer-assisted selection
of addresses. It is based on the ‘Infratest-Telephon
Master Sample,’ which was developed specifically for
telephone surveys and leads to bias-free, representative
samples. ‘Random-Digit Dialing’ reflects the standard
Working Group of German Market and Social Studies
Institute, developed according to Gabler and Häder
(Glemser 2002).
Screening criteria
Patients eligible for the questionnaire had been diagnosedwith
HZ by a physician during the previous 5 years, had
experienced HZ-related pain and were ≥50 years old. Initially,
only patients with HZ diagnosed during the previous
12 months were included, but this criterion was changed to
obtain the required sample size in a shorter timeframe (n=
280). Eligible respondents were classified as patients with
HZ (if pain lasted <3 months after rash onset) or patients
with PHN (if pain lasted ≥3 months after rash onset).
Questionnaire
Bespoke questions were developed. Some questions were
informed from standard QoL questionnaires and developed
further to enable evaluation of previous HZ episodes.
Patients were asked questions to assess the character-
istics of HZ/PHN pain. Patients also rated pain level on a
scale from 0 (‘no pain’) to 10 (‘pain as bad as you can
imagine’). Receipt of treatments or medications and the
pain relief that they provided were also assessed.
Further questions assessed the impact of HZ and PHN
on QoL. These included problems with usual daily
activities (work, studies, housework, family and leisure
activities), mobility and self-care, and the degree of pain/
discomfort and anxiety/depression. Limitations in the
activities of daily living were also assessed (including
moderate physical efforts and climbing flights of stairs) and
consequences for family members and the social circle of
the patient. Patients rated interference of pain from 0 (‘does
not interfere’) to 10 (‘completely interferes’) in the
following seven areas: general activity, mood, walking
ability, normal work, social relations, sleep and enjoyment
of life. Patients were asked about the impact of HZ and
PHN on work and sleep, as well as feelings of stress and
enjoyment. Patients rated the impact of HZ and PHN on
their overall QoL from 0 (‘not affected at all’) to 10
(‘highly affected’).
QoL data are presented for the following categories:
daily activities, mobility, work, sleep, mood, social/family
relations and overall QoL.
Statistical analysis
To identify 280 patients eligible for the main questionnaire
(approximately 50% aged 50–59 years and 50% aged
≥60 years), 11,009 subjects aged ≥50 years were contacted
and screened. Proportions and means were tested on a 90%
confidence level to assess if there were significant differ-
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ences in pain and QoL outcomes between the following
subgroups: (1) all patients versus only the proportion with
HZ diagnosed during the previous 12 months; (2) patients
50–59 years of age versus those ≥60 years of age; (3)
patients with HZ versus those whose pain persisted as PHN.
Multiple regression analysis was carried out on the
outcome of pain interference to assess which aspects had
a significant impact on QoL rating. Measurement was by
standardized β-coefficients. Normalized values (e.g.,
areas that have an impact on overall QoL) were set as
100%.
Results
Patient characteristics
A total of 11,009 respondents ≥50 years of age were
interviewed to identify 288 (2.6%) patients who had
experienced painful HZ diagnosed by a physician during
the previous 5 years. Pain duration after rash onset was
<3 months in 248 (89%) respondents (patients with HZ),
≥3 months in 32 (11%) respondents (patients with PHN)
and unknown in 8 (3%) respondents. Eight patients could
not be classified as having HZ or PHN, so results are
presented for 280 patients. Of these, 102 (36%) patients
were diagnosed with HZ during the previous 12 months.
Approximately equal numbers of patients were aged 50–
59 years (n=130; 46%) and ≥60 years (n=150; 54%).
Patient characteristics are displayed in Table 1. Most
patients were women (HZ, 64%; PHN, 81%), and mean age
was 63.5 years. There were no relevant differences in
characteristics between patient subgroups. Most patients
aged 50–59 years were employed full time (62%) and some
part time (11%), whereas most of those ≥60 years of age
were retired (81%).
Subgroup analysis of pain and QoL outcomes
Patients’ recollection of HZ pain and the impact of disease
on QoL were not affected by time since diagnosis or by
age. Outcomes were therefore similar for all patients versus
those diagnosed only within the previous 12 months and for
patients aged 50–59 years versus those aged ≥60 years. In
contrast, patients with PHN had statistically significantly
worse outcomes on every pain and QoL measure than
patients with HZ.
Patient-reported pain and treatment
In 60% of patients, HZ pain was spontaneous, with some
patients reporting spontaneous pain that increased with
friction (30%), pressing (28%) or contact with a cold object
(6%). HZ pain was described as ‘burning’ by 58% of
patients, as ‘electric shocks’ by 13% and as ‘painful cold’
by 8% of patients.
Pain levels were considerable, with mean pain scores in
all patients, patients with HZ and those with PHN,
respectively, of 6.3, 6.2 and 7.1 on average, and 7.2, 7.0
and 8.2 at worst (P<0.05 for patients with HZ versus
PHN). High levels of pain (score 8–10) on average and at
worst were reported by greater proportions of patients with
PHN than with HZ (Table 2A).
Although 97% of patients received treatment for HZ,
41% did not receive treatment within 3 days of rash onset.
Approximately 45% of patients required more than one
medication. Patients with PHN received significantly more
medications than patients with HZ (mean: 2.2 versus 1.6,
respectively, P<0.05) and yet experienced significantly less
pain relief (49% versus 67%, P < 0.05).
Impact of HZ and PHN on QoL
Interference with daily activities
Patients with PHN experienced a significantly higher level of
pain interference with general activity than those with HZ (P<
0.05) (Fig. 1). Multiple regression analysis showed that, of
the seven areas assessed, general activity had the highest
significant impact on QoL rating (33%; adjusted R2 0.57).
High proportions of patients experienced problems in
their usual daily activities (75%) and self-care (56%).
Patients with PHN had a greater prevalence of these
problems than those with HZ: usual daily activities (91%
versus 73%) and self-care (75% versus 54%). Many
patients were limited in moderate physical efforts (68%)
such as climbing flights of stairs (43%) (Table 2B).
Mobility
Patients with PHN experienced significantly greater pain
interference with walking ability than those with HZ (P<
0.05) (Fig. 1). The impact of walking ability on QoL rating
was not significant according to multiple regression
analysis. High proportions of patients experienced prob-
lems with mobility (63% overall), particularly those with
PHN (78% versus 61% of those with HZ). In 19% of
patients with PHN, mobility was sufficiently severe that
they were confined to bed.
Work
Of the 39% of interviewees who were employed while
affected by HZ/PHN, 65% reported absence from work
because of their disease. This was mainly due to pain
(60%), discomfort (60%), inability to concentrate (48%)
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Table 1 Patient characteristics
All HZ within previous 12months Age (years) 50–59 ≥60 Patient category
With HZ With PHN
All patients, n (%) 280 (100) 102 (36) 130 (46) 150 (54) 248 (89) 32 (11)
General characteristics
Sex, n (%)
Female 185 (66) 69 (68) 81 (62) 104 (69) 159 (64) 26 (81)
Male 95 (34) 33 (32) 49 (38) 46 (31) 89 (36) 6 (19)
Age, years, mean (SD) 63.5 (9.6) 63.5 (9.8) 54.9 (2.8) 70.9 (6.9) 63.5 (9.6) 63.3 (10.0)
Working status, %
Employed full-time (≥30 h per week) 33 35 62a 7 34 22
Employed part time (<30 h per week) 6a 3 11a 2 5 13
Not working/housewife/house husband 4 3 2 5 3 6
Unemployed 4 4 8a 1 4 3
Retired 51 53 15 81a 50 53
Not employed, reason not known 2 1 2 2 2 -
Other 0 1 1 - - 3a
a Significant differences between subgroups (all patients versus only the proportion with HZ diagnosed during the previous 12 months; patients aged 50–
59 years versus those aged ≥60 years; and patients with HZ versus those whose pain persisted as PHN)
Table 2 Pain and QoL outcomes
All
(n=280)
HZ within previous
12months (n=102)
Age (years)
50–59 (n=130)
≥60
(n=150)
Patient category
With HZ
(n=248)
With PHN
(n=32)
A. Level of pain
Pain score (0–10 scale), mean
On average 6.3 6.6 6.3 6.3 6.2 7.1*
At worst 7.2 7.3 7.3 7.0 7.0 8.2*
High pain level (score 8–10), % patients
On average 31 36 29 31 29 41
At worst 49 52 52 49 48 62
B. Limitations experienced on activities of daily living
Moderate physical efforts,a % patients
Limited at least a bitb 68 66 67 68 65 85
Limited a lot 25 28 23 27 23 41*
Climbing flights of stairs, % patients
Limited at least a bitb 43 45 45 41 40 65
Limited a lot 14 14 15 14 12 31*
Consequences for family members and social circle, % patients 53 53 53 54 50 81
C. Feelings of stress and enjoyment of leisure activities
Stressed at some timec, % patients 80 81 80 79 78 91
Stressed most of the time, % patients 22 21 20 23 19 41*
Did not enjoy leisure activitiesd, % patients 37 31 42 33 36 47
*P<0.05 versus corresponding group. a Moderate physical efforts include repositioning a table, vacuum cleaning and playing bowling. b Physical efforts
limited at least a bit includes ‘a bit’ and ‘a lot.’ c Stressed at some time includes ‘most of the time,’ ‘long time’ and ‘sometimes.’ d Did not enjoy leisure
activities includes ‘rarely enjoyed’ and ‘very rarely enjoyed;’ leisure activities include reading a book, listening to the radio or watching TV
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and health care visits (48%). Patients with PHN experi-
enced a significantly higher level of pain interference with
normal work than those with HZ (P<0.05) (Fig. 1). The
impact of normal work on QoL rating was not significant
according to multiple regression analysis.
Sleep
For many patients, sleep was ‘not quiet’ for at least some of
the time (overall, 60%; HZ, 57%; PHN, 88%) and for most
of the time (overall, 25%; HZ, 22%; PHN, 53%). Overall,
65% of patients did not have sufficient sleep most of the
time (HZ, 63%; PHN, 78%). Patients with PHN experi-
enced a significantly higher level of pain interference with
sleep than patients with HZ (P<0.05) (Fig. 1). A significant
impact of sleep on QoL rating was shown by multiple
regression analysis (18%; adjusted R2 0.57).
Mood
Patients with PHN experienced significantly higher levels
of pain interference with mood and enjoyment of life than
those with HZ (both P<0.05) (Fig. 1). Multiple regression
analysis showed a significant impact of mood (20%) and
enjoyment of life (16%) on QoL rating (adjusted R2 0.57).
Anxiety or depression as a result of HZ/PHN was
experienced by 40% of all patients; the proportion of patients
affected was higher for PHN than HZ (57% versus 37%).
Eighty percent of patients experienced stress during the time
they had HZ pain, particularly those with PHN (91% versus
78% of those with HZ) (Table 2C). Overall, 37% of patients
could not enjoy simple activities such as reading a book,
listening to the radio or watching television, while suffering
from HZ/PHN.
Social/family relations
Patients with PHN experienced significantly higher levels of
pain interference with social relations than patients with HZ
(P<0.05) (Fig. 1). A significant impact of social relations on
QoL rating was shown by multiple regression analysis (13%;
adjusted R2 0.57). Fifty-three percent of patients reported that
HZ/PHN had consequences for family members and their
social circle; the proportion of patients affected was greater
for PHN than for HZ (81% versus 50%, P<0.05) (Table 2B).
Overall impact of QoL
The impact of HZ/PHN on patients’ overall QoL was
considerable, with a mean affection score of 4.5 in all patients
and 4.2 versus 6.1 in patients with HZ versus PHN, respectively
(P<0.05). Greater proportions of patients with PHN than HZ
reported that their QoL was affected to a high level (35%
versus 17%) or medium level (50% versus 39%) (Fig. 2).
Discussion
This scientific survey assessed the impact of HZ and PHN
on the QoL and daily life of a German population aged
≥50 years who had experienced painful HZ during the
previous 5 years. This retrospective approach enabled
information to be captured on the full course of HZ
episodes, from rash onset to pain resolution. Patient-
reported outcomes clearly showed that HZ causes substan-
tial pain that seriously interferes with many aspects of
patients’ daily life, particularly sleep, mood and work. Pain
and QoL outcomes were not affected by time since
diagnosis or by age. Patients with PHN had considerably
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worse outcomes on every measure of pain and QoL than
those with HZ.
Studies suggest that high levels of patient-reported pain
and QoL burden are associated with HZ (Schmader 2001;
Chidiac et al 2001; Coplan et al. 2004; Schmader et al.
2007; Lydick et al. 1995; Katz et al. 2004) and PHN
(Chidiac et al 2001; Oster et al. 2005; Coplan et al. 2004;
van Seventer et al 2006; Mauskopf et al. 1994). In one
study, acute HZ pain affected all domains of patients’
activities of daily living (Lydick et al. 1995). There was a
clear correlation between increased intensity of pain and
greater interference with activities. The devastating effects
of HZ pain on patients’ QoL were comparable to the effects
of myocardial infarction and clinical depression. Two
observational studies that employed various QoL question-
naires demonstrated a substantial pain burden of HZ in the
first 30 days after rash onset, with moderate and severe
levels of pain commonly experienced (Schmader et al.
2007; Katz et al. 2004). In a study by Schmader et al.
(2007), worst pain 7 days after rash onset in 102 patients
with HZ (0–10 pain scale) was moderate (score 4–7) in 48
patients and severe (score 8–10) in 19 patients. Pain
interfered with all activities of daily living, particularly
enjoyment of life, sleep, general activities, leisure activities,
leaving the house and going shopping. In a study by Katz et
al. (2004), patients experienced average pain of moderate
intensity most of the time. Regression analysis showed that
significant independent contributions were made by sensory
pain burden to poorer physical functioning, overall pain
burden to poorer role and social functioning, and affective
pain burden to depression.
Greater levels of acute pain may contribute to the
development and severity of PHN. Psychosocial variables
such as measures of role functioning, personality disorder
symptoms and disease conviction may be additional risk
factors for PHN (Katz et al. 2005). This chronic complica-
tion remains refractory to pharmacological treatments and
prevention strategies (Johnson and McElhaney 2009). PHN
is thought to be associated with numerous constitutional
symptoms (chronic fatigue, anorexia, weight loss, physical
inactivity, insomnia) and psychological symptoms (depres-
sion, difficulty concentrating). PHN may interfere with
basic activities (e.g., dressing, bathing, mobility) and more
complex activities (e.g., traveling, shopping, cooking,
housework, social functioning) (Schmader 2002). Results
from a postal survey in the USA that used pain and QoL
questionnaires showed that patients commonly reported
moderate and severe levels of pain despite receiving
analgesic agents (Oster et al. 2005). PHN burden was
substantial and multidimensional, with all domains of daily
functioning and health status negatively affected. There was
a positive correlation between increasing pain severity and
the extent of the negative QoL impact. An observational
study that used patient questionnaires showed that the mean
pain level in patients with PHN was moderate (score 4.2)
(van Seventer et al. 2006). Seventy-eight percent of patients
reported the worst pain as moderate to severe. Pain
interference was reported on all seven domains of health
status, particularly mood, sleep and general activity. The
overall EuroQoL health valuation was 0.60. Substantial
proportions of patients received medications for depression,
anxiety and sleep disturbances related to PHN.
The burden of HZ and PHN is particularly important
given that HZ will manifest in one in four people within
their lifetime (Schmader 2001; Miller et al. 1993) and that
10–20% of patients with HZ ≥50 years old will experience
PHN (Oxman et al 2005; Gauthier et al. 2009; Scott et al.
2006; Johnson and Rice 2007). The prevalence of HZ and
PHN is expected to increase with the rising mean age of the
population (Brisson et al. 2001).
This retrospective survey has shown that pain levels in
patients with HZwere unacceptably high, particularly in those
who developed PHN. HZ treatment using antiviral agents may
reduce acute pain if given within 72 h of rash onset (Christo et
al. 2007; Breuer and Whitley 2007), but probably will not
ameliorate subsequent PHN (Johnson and McElhaney 2009).
Many patients in the present survey did not receive treatment
within this time window, nearly half of patients needed more
than one pain medication and patients with PHN experienced
significantly less pain relief than patients with HZ, despite
receiving more medications. Furthermore, the direct impact
of existing HZ treatments on QoL is not well studied.
Questions inspired by standard questionnaires consistently
showed that HZ and PHN had a substantial impact on daily
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activities, mobility, work, sleep, mood, social/family relations
and overall QoL. Mean pain interference was highest for
sleep, mood and normal work. Multiple regression analysis
revealed that general activity, sleep, mood, enjoyment of life
and relations with others all had a significant impact on QoL
rating. Patients with PHN had considerably worse outcomes
on every QoL measure compared with patients with HZ. Pain
and QoL data from patients diagnosed in the previous
12 months were consistent with data from all patients. This
demonstrated that patients’ recollection of the impact of
disease was not affected by time.
The high burden of HZ and PHN demonstrated in the
present study is similar to the findings from the observational
studies discussed above (van Seventer et al. 2006; Schmader
et al. 2007; Katz et al. 2004). The present survey proved to
be a useful tool for assessing patient-reported outcomes in
HZ and PHN. Therefore, the questionnaire has been
translated and adapted for use in six other countries. In lieu
of prospective studies, retrospective studies can provide
information more rapidly and with a larger sample size, and
may give important leads for the design of a prospective
study on the impact of HZ and PHN on patients’ QoL.
This study had certain limitations. First, there was a
relatively high proportion of patients diagnosed with HZ in
the previous 12 months versus the total number of patients
diagnosed in the last 5 years. This was because the screening
criterion regarding length of time since diagnosis was changed
after initial interviews to obtain the required sample size in a
shorter timeframe. Second, we evaluated the full course of HZ
episodes, and thus were not able to use currently available
validated questionnaires to evaluate pain and QoL, which only
evaluate current pain. However, this approach allowed a better
view of the patient’s global experience of their illness and
follows the approach taken in the pivotal SPS study that
assessed the HZ burden of illness using a severity-by-duration
measure (Oxman et al. 2008). Third, patients were required to
recall information about their HZ disease from up to 5 years
before the interviews. However, data clearly showed that
patients’ recollection of pain associated with HZ and PHN
and the impact of disease on QoL were not affected by time.
Finally, two-thirds of patients with HZ were female. Studies
have shown a higher prevalence of HZ in women than in
men (Gauthier et al. 2009; Bowsher 1999). In the present
telephone survey, many more women than men aged
≥50 years may have been willing to discuss their health.
Conclusions
Patients with HZ have high levels of pain, and this affects
many areas of their lives, including daily activities, mobility,
work, sleep and mood. Results of this survey clearly showed
that the development of PHN is consistently associated with
worse outcomes than HZ. This survey will contribute to an
increased awareness of the significant burden that patients
with HZ and PHN suffer. Recognition of this burden may lead
to improved prevention and management strategies.
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